Therapy Areas: Central Nervous System
Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier
8 June 2022 - - South Korea-based biotechnology company Genuv Inc and Israel-based Nanocarry Therapeutics, a private company developing a new class of therapeutics capable of crossing the Blood-Brain Barrier, have inked an agreement to collaborate on the development of an experimental drug to treat metastatic lung cancer, the companies said.

Specifically, this collaboration will further develop GNUV201 to treat metastatic tumors in the brain, using Nanocarry's AxS platform to cross the BBB.

GNUV201 is an experimental, novel anti-PD-1 monoclonal antibody developed with Genuv's proprietary antibody development platform Shine Mouse. GNUV201 exhibits strong cross-reactivity to both human and mouse PD-1, increasing the likelihood that animal models of disease are predictive of human clinical results.

The experimental drug candidate also demonstrates superior binding affinity compared to Keytruda and Opdivo. The goal is to deliver this powerful cancer-fighting experimental antibody to treat metastatic tumors in the brain from non-small cell lung cancer (NSCLC).

The two firms have applied for a grant from the Korea-Israel Industrial R and D Foundation (KORIL-RDF) to support an initial feasibility study including in vitro and in vivo studies to explore targeting the brain with antibodies to treat tumors.

Genuv Inc. is in discovering drugs for central nervous system disorders and advanced antibody therapies.

The Atriview drug screening platform uses cell phenotypic and biomarker analyses to discover substances for the development of neurodegenerative disease treatment.

The company's Shine Mouse and NuvoMab platform generate antibodies with superior affinity, solubility, and stability.

Based in Seoul, Korea, Genuv launched its first clinical trial in Korea in 2020. Genuv uses scientific imagination and unique platform technologies to overcome the challenges in debilitating diseases.

Shine Mouse is Genuv's proprietary platform for developing antibodies with greater diversity compared to conventional mouse antibodies.

Its antibodies are able to recognize new and different epitopes, potentially enabling the use of antibodies to treat many more diseases.

Antibodies developed with Shine Mouse also exhibit powerful cross-reactivity to human and mouse PD-1.

Shine Mouse is a powerful tool in the development of advanced biologics to treat cancer and other life-altering diseases.

Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases.

Using a proprietary "Plug and Play" approach, Nanocarry's AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.


Related Headlines